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The prevalence of allergic disease has increased dramatically in Western countries over
the past few decades. The hygiene hypothesis, whereby reduced exposure to microbial
stimuli in early life programs the immune system toward a Th2-type allergic response, is
suggested to be a major mechanism to explain this phenomenon in developed populations.
Such microbial exposures are recognized to be critical regulators of intestinal microbiota
development. Furthermore, intestinal microbiota has an important role in signaling to the
developing mucosal immune system. Intestinal dysbiosis has been shown to precede the
onset of clinical allergy, possibly through altered immune regulation. Existing treatments
for allergic diseases such as eczema, asthma, and food allergy are limited and so the focus
has been to identify alternative treatment or preventive strategies. Over the past 10 years,
a number of clinical studies have investigated the potential of probiotic bacteria to amelio-
rate the pathological features of allergic disease. This novel approach has stemmed from
numerous data reporting the pleiotropic effects of probiotics that include immunomodu-
lation, restoration of intestinal dysbiosis as well as maintaining epithelial barrier integrity.
In this mini-review, the emerging role of probiotics in the prevention and/or treatment of
allergic disease are discussed with a focus on the evidence from animal and human studies.
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INTRODUCTION
Allergic diseases have become a major public health problem over
the past few decades. The prevalence of eczema (atopic dermatitis),
food allergy, and asthma have all increased dramatically during this
time, particularly in Western society. It is believed that between 20
and 30% of individuals living in Western countries suffer at least
one form of allergic disease (Zuercher et al., 2006). The impact
on health care systems and society in general is significant, with
allergic disease one of the most common causes of chronic illness,
hospital admissions as well as school absenteeism (Su et al., 1997).
Furthermore, the emotional and psychological burden on parents
and families is substantial (Beattie and Lewis-Jones, 2006). Parents
of children with food allergy have reported a diminished quality
of life compared to parents of children with rheumatological con-
ditions, indicating a substantial psychological burden associated
with these types of diseases (Primeau et al., 2000).
Allergic diseases are characterized by an inappropriate T-helper
(Th)-2 cell immune response to environmental or food anti-
gens (Zuercher et al., 2006). Activation of this response leads
to the secretion of IL-4, IL-5, and IL-13 and the production of
allergen-specific IgE. In the classical paradigm, the induction of
Th2 cytokine responses also act to suppress Th1 activity (mainly
through IFN-γ) which helps maintain the allergic phenotype. Sta-
bility of this Th1/Th2 balance is also regulated at the gene level
through the relative functions of the GATA-3 (Th2) and T-bet
(Th1) transcription factors. However, novel insights into dendritic
cell (DC) and regulatory T cell (Treg) biology have revealed impor-
tant critical effector functions of these populations in the control
of allergic responses. Several studies have shown that allergic
individuals have reduced Treg numbers and function (Shreffler
et al., 2009; Palomares et al., 2010), while mutations in the Treg
transcription factor FoxP3 results in severe immune-mediated
diseases (Goodman et al., 2012).
The mechanisms that drive the development of allergic dis-
ease in early life are yet to be fully understood. One of the more
widely recognized ideas relates to intestinal microbiota, where
the composition and profile of commensal bacteria interact with
the developing immune system. Such interactions can influence
immune maturation, potentially leading to Th2-polarized allergic
responses. As such, prophylactic or therapeutic strategies that tar-
get intestinal microbiota have been the subject of intense scientific
research. This review article will discuss the critical function of
intestinal microbiota and the evidence for the beneficial effects of
probiotics in the prevention and/or treatment of allergic disease.
HYGIENE HYPOTHESIS, INTESTINAL MICROBIOTA, AND
IMMUNE DEVELOPMENT
Reduced exposure to microbes early in life is suggested to be one
of the main mechanisms to account for the increasing prevalence
of allergic diseases over the past few decades. Commonly referred
to as the “hygiene hypothesis,” this was originally described by
Strachan (1989) and associated reduced microbial contact with
increased incidence of hay fever. Today, reduced microbial expo-
sures (and the rise in allergic conditions) have been attributed to
Western lifestyle factors such as diet, antibiotic use, vaccinations,
reduced household size, and improved hygiene. Epidemiological
studies have shown that children raised on farms during early life
have a reduced risk of developing allergic disease such as eczema
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or asthma (Riedler et al., 2001), while prenatal farm exposure
modulates atopic sensitization later in life (Ege et al., 2006).
The human intestinal microbiota represents the most signifi-
cant microbial exposure for the developing infant. As many as 1015
microbes consisting of 1,000 different strains are said to colonize
gastrointestinal tract (GIT; Molloy et al., 2012). Under normal
conditions, these bacteria have beneficial roles to the host such
as digestion, immune development, and the control of intesti-
nal epithelial cell growth and differentiation (Martin et al., 2010).
Commensal bacteria are also important in the fermentation of
undigestible dietary fibers, a process which produces large quanti-
ties of short-chain fatty acids in addition to the release of essential
vitamins (Cummings and Macfarlane, 1997).
Colonization by commensal bacteria occurs immediately after
birth and continues throughout the first year of life (Arboleya et al.,
2012). Acquisition of intestinal microbiota can be influenced ini-
tially by mode of delivery, maternal microbiota as well as host
genetic factors and later by breastfeeding and other environmen-
tal factors (Penders et al., 2006; Bisgaard et al., 2009; Fallani et al.,
2010; Bezirtzoglou et al., 2011; van Nimwegen et al., 2011; Azad
and Kozyrskyj, 2012).
One of the most important functions that intestinal microbiota
have is development of the host immune system. It provides the
largest source of antigenic stimuli that assists the programming
of postnatal immunity through maturation of the gut-associated
lymphoid tissue (GALT) while promoting tolerogenic responses
to innocuous antigens, including foods. This is primarily achieved
via mucosal antigen sampling by pattern recognition receptors
(PRRs) expressed on intestinal epithelial cells and innate immune
cells (Rautava and Walker, 2007). These specialized receptors bind
to microbial-associated molecular patterns (MAMPs) that are
expressed on a variety of commensal micro-organisms (Amdekar
et al., 2010). An important member of the PRRs is the Toll-
like receptors (TLR) that recognize a range of MAMPS such
as lipoteichoic acid (TLR2) and lipopolysaccharide (TLR4) on
Gram-negative and Gram-positive bacteria, respectively (Bauer
et al., 2007). These signals delivered by commensal bacteria to
TLRs determine the nature of the immune response and results in a
combination of regulatory and inductive effector functions involv-
ing DCs, Treg, chemokines, and cytokines to prevent Th2-type
allergic responses as well as other inflammatory diseases (Braga
et al., 2011; Rutella and Locatelli, 2011).
Germ-free (GF) mice have provided the best evidence for the
role of microbiota on the GALT, as these mice have extensive
defects in GALT development. A number of studies have shown
that GF mice have reduced intraepithelial lymphocytes, Peyer’s
patches with impaired germinal center development as well as
fewer IgA secreting plasma cells and CD4+ T cells in the lamina
propria (Bandeira et al., 1990; Macpherson et al., 2001; Martin
et al., 2010). Reconstitution with various microbial species can
restore GALT function in these mice, further supporting the role
of microbiota in immune development (Rakoff-Nahoum et al.,
2004). Furthermore, while GF mice do not develop tolerance to
parenterally administered antigen owing to a lack of Treg cells,
the oral introduction of microbes was able to establish tolerance
(Bruzzese et al., 2006). A recent study found that GF mice had
decreased pro-IL-1β levels compared to wild type, suggesting an
impaired ability to promote Th17 cells essential for host defense
(Shaw et al., 2012). Furthermore, reconstitution with segmented
filamentous bacteria, clostridia and Alcaligenes was able to stimu-
late IgA production in GF mice (Talham et al., 1999; Umesaki and
Setoyama, 2000; Obata et al., 2010). Moreover, when GF mice were
given a high oral dose of ovalbumin (OVA) followed by a systemic
challenge to induce tolerance, the Th2 response was not affected;
however reconstitution with Bifidobacterium infantis in these mice
was sufficient for oral tolerance to occur (Sudo et al., 1997). Also,
antibiotic-treated mice had altered microbiota that was associ-
ated with an increased severity in airway inflammation as well as
reduced Treg numbers in the colon (Nagler-Anderson, 2000; Rus-
sell et al., 2012). It is reported that the composition of intestinal
microbiota may not be able to be restored to its pre-treatment
state following antibiotic use (Blaser, 2011; Dethlefsen and Rel-
man, 2011). These data highlight the important role of microbiota
in immune development and the potential for immune dysregu-
lation such as allergy and autoimmunity when there is intestinal
dysbiosis (Sjogren et al., 2009; Larsen et al., 2010; Vijay-Kumar
et al., 2010; Bisgaard et al., 2011).
A relationship between intestinal microbiota and allergic dis-
ease is well-established (Bisgaard et al., 2011; Johansson et al., 2011;
van Nimwegen et al., 2011). Infants with allergic parents are at least
twice more likely to develop allergic diseases than non-allergic par-
ents (Dold et al., 1992; Bisgaard et al., 2011). Several epidemiologi-
cal studies have reported that microbiota differences exist between
allergic and non-allergic infants as well as between countries with
high or low allergy prevalence rates (Bjorksten et al., 1999, 2001;
Kalliomaki et al., 2001a; Watanabe et al., 2003). In a recent study
by Johansson et al. (2011) infants from non-allergic parents were
more frequently colonized by healthy lactobacilli, suggesting a role
for maternal microbiota in protection from allergic disease. Other
early studies have shown that healthy infants are usually colonized
with infant-type B. longum and B. breve species while infants with
eczema are more frequently colonized with adult-type B. adoles-
centis (He et al., 2001; Ouwehand et al., 2001). Previous studies
have also found reduced microbial diversity, accompanied with
lower numbers of lactobacilli and bifidobacteria, and early life col-
onization by Staphyloccocus aureus and Clostridum difficile were
associated with the development of allergic disease later in life
(Penders et al., 2007; Sjogren et al., 2009).
The ability of intestinal microbiota to influence immune devel-
opment has led to novel interventions that exploit these microbiota
differences in allergic individuals. In recent years, probiotic bacte-
ria have been used with some success in preventing allergic disease
in high-risk infants.
PROBIOTICS
The WHO/FAO (Food and Agriculture Organization of the UN)
define probiotics as “live micro-organisms, which when adminis-
tered in adequate amounts, confer a health benefit on the host”
(WHO, 2001; Reid, 2005). The identification and use of probiotics
date back to the early twentieth century (Shortt,1999;Anukam and
Reid, 2007). Professor Elie Metchnikoff, considered the grandfa-
ther of modern probiotics, observed that the regular consumption
of lactic acid bacteria in fermented dairy products, such as yogurt,
was associated with enhanced health and longevity in Bulgarian
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peasants (Anukam and Reid, 2007). At the time, it was believed
that fermented milk contained lactic acid bacteria that decreased
the pH of the gut and suppressed the growth of proteolytic bacte-
ria (harmful bacteria). Since then, probiotic research as increased
exponentially and the benefits of probiotics have been demon-
strated in a number of studies for allergy, diarrheal diseases, and
inflammatory conditions.
The history of probiotic use together with the wide availabil-
ity of probiotic supplements over the counter suggests a high
degree of safety in humans. Indeed, probiotics are demonstrated
to be safe when given to both infants and adults (Tang, 2009).
In general, probiotic bacteria need to fulfill several ideal criteria
in order to elicit their beneficial effects, summarized in Table 1
(Tuomola et al., 2001). In taxonomy terms, the most commonly
used probiotic bacteria are species of the genera Lactobacillus and
Bifidobacterium. However, probiotic effects are strain and species-
specific, and their biological activity can vary depending on the
selected probiotic (Licciardi and Tang, 2011). Therefore, careful
consideration should be given to the probiotic strain selected for
use, and should be based on supporting in vitro and in vivo data.
PROBIOTIC MECHANISM OF ACTION
There are several mechanisms by which probiotics are proposed to
exhibit beneficial effects on the host and these can be broadly clas-
sified as microbiological, epithelial, or immunological in nature
(Figure 1; Oelschlaeger, 2010). Firstly, probiotic bacteria are able
to modulate the composition of intestinal microbiota. It has been
shown in recent studies that supplementation with probiotic bac-
teria such as Lactobacillus rhamnosus GG (LGG) or L. casei can
modulate the composition of intestinal microbiota of allergic
infants by reducing pathogenic bacteria such as clostridia while
enhancing or maintaining beneficial bifidobacteria levels in the
stool (Lahtinen et al., 2009; Klewicka et al., 2011). This is primar-
ily achieved through changes in the intestinal lumen environment
such as lowering the pH level and competition for nutrients that
result in physiologically restrictive conditions for the growth of
pathogenic bacteria (Asahara et al., 2004; Todorov et al., 2011).
Probiotics can also compete with other micro-organisms for bind-
ing to specific receptors on host epithelial cells, thereby preventing
potential pathogen invasion (Mukai et al., 2002; Setia et al., 2009).
Transient colonization of the GIT by Bifidobacteria have been pre-
viously demonstrated as early as 1 week after supplementation
(Langhendries et al., 1995) indicating that these effects can be
Table 1 | Characteristics of an ideal probiotic.
Characteristic Functional advantage
Local GIT environment Resistance to pH, bile, and digestive enzymes
Epithelial cell adherence Prevent binding of pathogens or food antigens
Human origin Increased likelihood of biological effectiveness
Anti-microbial activity Direct toxicity to harmful bacteria, viruses,
fungi, and parasites
Safety Well-tolerated, important for clinical use
GIT, gastrointestinal tract.
induced rapidly. Moreover, Bifidobacteria and Lactobacilli pro-
biotic treatment can modulate infant microbiota composition
during early life (Mohan et al., 2006; Stratiki et al., 2007; Lahtinen
et al., 2009) as well as stimulate the growth of other beneficial
indigenous bacterial species in animals and humans (Tannock
et al., 2000; Sui et al., 2002; Ohashi et al., 2007). Modulation of
colonization by probiotic bacteria can prevent harmful pathogens
from persisting in the intestinal tract, thereby facilitating clearance
by the immune system. In addition, some probiotic bacteria pro-
duce bacteriocins that inhibit the growth of pathogenic bacteria
(Heng et al., 2011). For example, a bacteriocin produced by L. aci-
dophilus La-14 repressed the growth of L. monocytogenes (Todorov
et al., 2011), consistent with previous findings with other probiotic
species against mycobacterium (Todorov et al., 2008).
Another mechanism of probiotic action is directed at the
epithelial surface where they modulate the integrity of the epithe-
lial cell barrier and regulate the function and expression of tight
junction proteins and mucus secretion (Caballero-Franco et al.,
2007). The probiotic Escherichia coli strain Nissle 1917 was shown
to increase both ZO-2 expression and PKC signaling associated
with enhanced barrier function in T84 epithelial cells (Zyrek et al.,
2007). Increased transepithelial resistance as well as enhanced
tight junction protein phosphorylation of actinin and occludin
was detected following treatment of enteroinvasive E. coli infected
cells with live Streptococcus thermophilus and Lactobacillus aci-
dophilus (Resta-Lenert and Barrett, 2003). Probiotics also produce
significant quantities of short-chain fatty acids (SCFA) following
fermentation of dietary fiber and exert potent anti-inflammatory
and epithelial activities (O’Keefe et al., 2011; Macia et al., 2012).
Butyrate, a common SCFA, was found to modulate the expression
of certain tight junction proteins such as cingulin,ZO proteins,and
occludin to improve the epithelial barrier integrity (Bordin et al.,
2004; Peng et al., 2009). Another SCFA, acetate, has been shown
to reduce inflammatory lesions in animal models of asthma and
colitis (Maslowski et al., 2009). Neutrophils express the G protein-
coupled receptors GPR41 and GPR43 that can bind SCFAs and
mediate their anti-inflammatory effects (Maslowski et al., 2009).
This effect for SCFAs was demonstrated through modulation of
NFκB and cytokine activities in vitro (Tedelind et al., 2007). It
has also been proposed that SCFAs exhibit histone deacetylase
inhibitory properties that modify chromatin structure/function
and downstream gene expression (Licciardi et al., 2010).
Various studies have found that probiotic bacteria can modu-
late both innate and adaptive immunity. The activation of TLRs
by microbes initiates the immune response which can result in
systemic and mucosal effects (Castillo et al., 2011). Lactobacilli
attenuated pro-inflammatory responses by regulating NFκB activ-
ity (Yang et al., 2012), while other probiotics reduced TNF-α
induced NFκB activation in a TLR9-dependent manner (Ghadimi
et al., 2010). Probiotic bacteria also modulated DC maturation
toward an anti-inflammatory IL-10 profile (Borchers et al., 2009).
Moreover, human monocyte-derived DCs (MoDCs) treated with
a probiotic culture supernatant released IL-10 that enabled the dif-
ferentiation and survival of Treg (Rimoldi et al., 2005). B. animalis
and B. longum were shown to induce IFN-γ and TNF-α release
by DCs while in contrast, only B. bifidum could induce Th17 cell
activation through the release of IL-17 by DCs (Lopez et al., 2010).
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FIGURE 1 | A summary of probiotic biological effects.
LGG was also found to be a potent inducer of DC maturation while
L. delbrueckii stimulated the secretion of both pro-inflammatory
cytokines and IL-10 (Elmadfa et al., 2010).
There is a significant body of evidence demonstrating that pro-
biotics modulate the Th1/Th2 balance to prevent the development
of inflammatory diseases such as allergy. Human peripheral blood
mononuclear cells (PBMCs) from allergic patients in vitro treated
with several lactic acid bacteria including L. plantarum, L. lac-
tis, L. casei, and LGG prior to stimulation with house dust mite
had reduced Th2 responses characterized by lower IL-4 and IL-5
secretion (Pochard et al., 2002). Several other studies have shown
similar cytokine effects, with LGG and L. bulgaricus inducing IL-
1β, IL-6, IL-8, and TNF-α by PBMCs in vitro (Niers et al., 2005)
while other lactic acid bacteria increased IFN-γ, TNF-α as well
as IL-10 (Miettinen et al., 1998). The role of probiotics on Treg
activity has also been reported. Both LGG and B. lactis Bb12
suppressed allergic symptoms in a mouse model of asthma by
inducing TGF-β secreting Tregs (Feleszko et al., 2007). In another
study, L. acidophilus W55 but not L. plantarum W62 was able
to induce functional FoxP3+ Treg from CD25− cells in PBMCs
from healthy adults, further supporting the species-specific effects
of probiotics (de Roock et al., 2010). Other effects of probiotics
that make them suitable for modulation of allergic disease include
stimulation of mucosal IgA levels as well as allergen-specific B and
T cell responses (Prescott and Bjorksten, 2007; Marschan et al.,
2008; Maldonado Galdeano et al., 2011).
EVIDENCE FOR PROBIOTIC EFFECTS IN ANIMAL MODELS OF
ALLERGIC DISEASE
The evaluation of probiotics in RCTs for the prevention and/or
treatment of allergic disease are often the result of mechanistic
data provided by in vitro experiments as well as animal models.
Many studies have examined the use of probiotics in animal mod-
els of allergic disease, often with convincing results. Prebiotics,
defined as a selectively fermented ingredient that allows specific
changes in the composition and/or activity of intestinal micro-
biota to confer a health benefit on the host (Charalampopoulos
and Rastall, 2012), are often given in combination with probiotics
(termed symbiotic) however the biological effects of prebiotics are
more limited and are not described in this review.
Probiotics have been shown to be effective in animal mod-
els of atopic dermatitis (eczema). Oral L. rhamnosus CGMCC
supplementation to pregnant mice was shown to prevent the devel-
opment of atopic dermatitis (eczema) when the newborns were
also treated for the first 12 weeks, with reduced clinical symp-
toms, total plasma IgE levels and enhanced IFN-γ in skin biop-
sies (Curran, 2011). However, this effect was not observed when
treatment was started 1 week after the onset of disease. Similar
effects were observed by these authors when L. johnsonii NCC533
(La1) was given to mice for 4 weeks during the weaning period
(Charalampopoulos and Rastall, 2012). In a dog model of atopic
dermatitis, reduction in allergen-specific IgE levels were detected
following treatment with LGG but no significant changes in clin-
ical signs were observed (Cook et al., 2012). Using NC/Nga mice,
several studies with various lactobacilli strains have shown bene-
ficial effects in the prevention of atopic dermatitis-like symptoms,
including increased sIgA production (Abrahamsson et al., 2012),
reduced IgE (Wakabayashi et al., 2008), upregulated IL-10 (Abra-
hamsson et al., 2012), and reduced Th2 cytokine secretion in vitro
(Klewicka et al., 2011), suggesting that probiotics mediate their
activity through several mechanisms. In a mouse model of atopic
dermatitis induced by house dust mite and dinitrochlorobenzene,
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treatment with a probiotic mixture containing L. acidophilus, L.
casei, L, reuteri, B. bifidum, and Streptococcus thermophilus inhib-
ited clinical progression as well as attenuating total and allergen-
specific IgE levels, IL-4, IL-5, IL-10, and IL-13 levels associated
with increased CD4+FoxP3+ Tregs in the ear (Klewicka et al.,
2011).
The mouse allergic airway disease (AAD) model of human
asthma is frequently used for the examination of probiotic effec-
tiveness. Hougee et al. (2010) revealed that of 6 probiotic strains
tested in an OVA AAD model, B. breve M-16V had the most poten-
tial due to the ability to improve lung function as well as reduce
eosinophil numbers, OVA-specific IgE, IL-4, IL-5, and IL-10 lev-
els in the bronchoalveolar lavage fluid (BALF). Treatment of mice
with L. casei plantarum Lcr35 prior to OVA sensitization was found
to prevent the development of airway hyperresponsiveness (AHR),
BALF eosinophils as well as total serum IgE levels compared to
mice treated with Lcr35 after OVA sensitization but before OVA
challenge (Yu et al., 2010). Not all probiotics have been shown
to be effective however. In one study, L. reuteri but not L. sali-
varius was able to significantly attenuate AAD by way of reduced
airway eosinophils, AHR and TNF-α, IL-5 and IL-13 levels in the
BALF (Forsythe et al., 2007). Subsequent studies by these authors
showed that L. reuteri induced CD4+CD25+FoxP3+ Treg in
the spleen of treated mice that were able to prevent the devel-
opment of AAD following adoptive transfer into OVA-sensitized
mice (Karimi et al., 2009). These results were in support of the
study by Feleszko et al. (2007) where administration of LGG but
not B. lactis Bb12 was able to suppress allergen-induced T cell
proliferation associated with upregulated TGF-β secreting T cells
and FoxP3+ cells in the lymph nodes. LGG was also shown to
suppress AAD in mouse offspring following maternal administra-
tion along with reduced expression of TNF-α, IL-5, and IL-10 but
not IL-14 or IL-14 by splenic lymphocytes (Blumer et al., 2007).
Recent evidence suggests that maternal supplementation with ben-
eficial bacteria may induce epigenetic changes in the progeny, with
evidence showing that the beneficial farm-derived Acinetobacter
lwoffii F78 bacterium was able to prevent the development of an
asthma phenotype via histone modification at the IFNG promoter
(Brand et al., 2011).
Less data is available from animal models of food allergy
although existing evidence supports a role for probiotics. In a
pig model of egg allergy, Lactococcus lactis pre-treatment was
shown to reduce clinical symptoms, lower IL-4 and IL-10 levels
in mitogen-stimulated mononuclear cell supernatants but lower
IgG1/IgG2 and IgE/IgG2 ratios indicating a Th1 bias compared
to untreated pigs (Rupa et al., 2011). The use of the probiotic
mixture VSL#3 also suppressed the allergic response following
shrimp tropomyosin sensitization in mice (Schiavi et al., 2011).
Reduced histamine release, symptom scores, and IgE levels were
associated with VSL#3 treatment as well as lower IL-4, IL-5, IL-3
but higher IFN-γ, TGF-β, and IL-10 levels in the intestine. Other
studies using the OVA model of egg allergy have demonstrated
anti-allergic effects for several probiotic species including L. aci-
dophilus (Kim et al., 2008; Finamore et al., 2012), B. lactis (Kim
et al., 2008), LGG (Finamore et al., 2012), and L. lactis (Zuercher
et al., 2012). L. casei Shirota was unable to suppress peanut allergic
responses in rats characterized by increased levels of both IgG and
IgE as well as IFN-γ and IL-4 levels secreted by in vitro stimulated
splenic and mesenteric lymph node cells (de Jonge et al., 2008).
EVIDENCE FOR THE CLINICAL EFFECTS OF PROBIOTICS IN
ALLERGIC DISEASE
Over the past 15 years, a number of studies have examined the clin-
ical benefit of probiotics for the prevention or treatment of allergic
disease. Most of these have focused on eczema since this is fre-
quently the first manifestation of allergic disease (refer Table 2 for
a summary of probiotic bacteria with beneficial effects in eczema),
while a few studies have looked at other outcomes such as asthma
and food allergy.
ALLERGY TREATMENT STUDIES
Table 3 summarizes the major outcomes of probiotic intervention
studies for the treatment of eczema. Initial studies of probiotic
treatment with LGG, Bifidobacterium lactis Bb12 or B. breve M-
16V for up to 8 weeks demonstrated improved eczema symptoms
in infants and children compared to placebo treatment, although
these involved relatively small sample sizes (Majamaa and Isolauri,
1997; Isolauri et al., 2000; Hattori et al., 2003). In the study by
Weston et al. (2005) significantly reduced eczema severity (SCO-
RAD) was observed over an 8-week L. fermentum VR1-003PCC
treatment period, however this was not different when compared
to the placebo group. In contrast, these effects of probiotics have
not been confirmed in more recent and larger scale trials (Rosen-
feldt et al., 2003; Viljanen et al., 2005a; Brouwer et al., 2006; Folster-
Holst et al., 2006; Sistek et al., 2006; Gruber et al., 2007). However,
despite the lack of a beneficial effect in these studies, subgroup
analysis revealed improved SCORAD following LGG (Viljanen
et al., 2005a) or a combined L. rhamnosus HN001 and B. lactis
Table 2 | Probiotics demonstrating a beneficial effect in clinical studies
of eczema.
Type of clinical study Probiotic
Treatment Lactobacillus rhamnosus GG
Lactobacillus rhamnosus HN001
Lactobacillus sakei KCTC
Lactobacillus acidophilus La-5
Lactobacillus acidophilus*
Lactobacillus salivarius LS01
Lactobacillus fermentum VR1
Bifidobacterium lactis Bb12
Bifidobacterium lactis UABLA-12**
Bifidobacterium bifidum
Prevention Lactobacillus rhamnosus GG
Lactobacillus rhamnosus LC705
Lactobacillus paracasei F19
Bifidobacterium breve Bb99
Propionibacterium freudenreichii***
*In combination with B. bifidum, L. casei, L. salivarius.
**In combination with L. acidophilus DDS-1 and fructo-oligosaccharides
(prebiotic).
***In combination with galacto-oligosaccharides (prebiotic).
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HN019 (Sistek et al., 2006) treatment in children with atopy/IgE-
associated eczema. In the study by Viljanen et al. (2005b), the
clinical effects observed for LGG were associated with low IL-6 and
C-reactive protein (CRP) levels indicative of low-grade inflam-
mation; it was suggested that this may trigger anti-inflammatory
responses such as elevated IgA and IL-10 to suppress the ongoing
allergic/inflammatory process.
Two studies have reported a positive effect of probiotic sup-
plementation for the treatment of eczema. An 8-week treatment
with the probiotic/prebiotic mixture containing L. acidophilus
DDS-1, B. lactis UABLA-12, and fructo-oligosaccharides (FOS)
was observed to reduce SCORAD to a greater extent than placebo
(Gerasimov et al., 2010) while a 12-week L. sakei KCTC 10755BP
treatment in young children also lowered SCORAD and improved
mean disease activity by three-fold over placebo-treated children
(Woo et al., 2010). In the recent study by Yesilova et al. (2012),
children aged 1–3 years with a history of eczema were treated with
a combination of B. bifidum, L. acidophilus, L. casei, and L. salivar-
ius for 8 weeks and found reductions in SCORAD as well as serum
cytokines IL-5, IL-6, IFN-γ, and total serum IgE levels, but not
IL-2, IL-4, IL-10, or TNF-α compared to the placebo group. How-
ever, the use of a combined probiotic and prebiotic formulation
(synbiotic) containing B. breve M-16V and a mixture of galacto-
and fructo-oligosaccharides (GOS/FOS) were unable to improve
eczema severity compared to placebo although an improved SCO-
RAD was observed for infants with IgE-associated eczema (van der
Aa et al., 2010). In a study by Wu et al. (2012), treatment of chil-
dren suffering moderate to severe eczema with a combination of
L. salivarius and FOS for 8 weeks resulted in significantly reduced
severity scores compared to FOS only, although no placebo group
was used for baseline comparison. A similar result was found in
adults treated with L. salivarius LS01 for 16 weeks, with signifi-
cantly lower SCORAD compared to placebo as well as decreased
IFN-γ, IL-2, and Th1/Th2 cytokine ratio (Drago et al., 2011).
The evidence for a beneficial effect of probiotics in the treat-
ment of eczema based on several systematic reviews and meta-
analyses are inconclusive (Boyle et al., 2008; Lee et al., 2008; Tang
et al., 2010). In particular, the Cochrane meta-analysis (Boyle et al.,
2008) found no significant reduction in eczema symptoms or
severity by probiotics compared to placebo. Moreover, analysis
of those participants with atopy or with severe disease was not
able to identify a subset of patients that may benefit from pro-
biotic therapy. Explanations for the lack of a probiotic treatment
effect could be due to the significant heterogeneity between stud-
ies, both in the study populations and the selection of probiotic
strains used. It is possible that the activity of potentially beneficial
probiotic bacteria may be masked in pooled analyses. Therefore,
the ability of probiotics to improve eczema outcomes cannot be
completely excluded.
In the context of food allergy, tolerance to food antigens during
infancy is a critical step in the development of the immune sys-
tem. Given the ability of probiotics to modulate mucosal responses
such as IgA production, DC, and Treg numbers as well as main-
taining the GIT epithelial barrier integrity, it is no surprise that
they have been investigated in food allergic individuals (Isolauri
et al., 1993; Majamaa and Isolauri, 1997; Pelto et al., 1998). Cur-
rently, no evidence has been shown to suggest that probiotics can
induce clinical tolerance to food antigens. However, the few studies
that have examined whether probiotic treatment can modify the
natural course of food allergy have not demonstrated an effect.
In a randomized double-blind placebo-controlled study of 119
infants with challenge confirmed cow’s milk allergy, supplementa-
tion with L. casei CRL431 and B. lactis Bb12 for 12 months did not
affect acquisition of tolerance to cow’s milk (Hol et al., 2008). In
another study in children less than 3 years of age sensitized to egg,
peanut, or cow’s milk, treatment with a probiotic mix containing
Lactobacillus and Bifidobacterium species for 3 months failed to
influence sensitization (SPT size or allergen-specific IgE levels) or
ex vivo immune responses (Flinterman et al., 2007). In addition,
one study that examined SCORAD outcomes in children with
eczema and cow’s milk allergy also found no effect of probiotic
treatment (Viljanen et al., 2005a).
In contrast to those studies on eczema outcomes, there are lim-
ited studies on the effect of probiotic treatment for asthma. In
a small study, L. acidophilus treatment had no impact on clini-
cal asthma in adults (Wheeler et al., 1997). Furthermore, adults
given B. breve M-16V and GOS/FOS (prebiotic) did not show
any improvement in lung function or bronchial inflammation
although IL-5 levels were reduced (van de Pol et al., 2011). A
complicating factor is that several studies include mixed popula-
tions involving patients with asthma and allergic rhinitis rather
than either condition alone. This makes demonstration of any real
benefit more difficult. Indeed, while no benefit was observed in
studies involving heterogeneous populations treated with L. casei
(Giovannini et al., 2007) or LGG (Helin et al., 2002), one study
of children with asthma/allergic rhinitis treated with L. gasseri
showed significant improvements in clinical symptoms as well as
reduced allergic cytokine levels such IL-13 (Chen et al., 2010). In
summary, the conflicting data from the few reported studies do
not support the use of probiotics for the treatment of asthma.
ALLERGY PREVENTION STUDIES
Prevention of allergic disease remains the greatest challenge for
clinicians. While a paucity and evidence – mainly inconclusive –
exists for the use of probiotics in the treatment of allergic disease,
several clinical trials have been successful in the use of probiotics
for the prevention of allergic disease. At present, a total of 14 ran-
domized controlled trials evaluating various probiotics have been
reported, mostly involving infants of families with a history of
allergic disease (summarized in Table 4; Kalliomaki et al., 2001b;
Rautava et al., 2006; Abrahamsson et al., 2007; Kukkonen et al.,
2007; Taylor et al., 2007; Huurre et al., 2008; Kopp et al., 2008;
Wickens et al., 2008; Niers et al., 2009; Soh et al., 2009; West et al.,
2009; Dotterud et al., 2010; Kim et al., 2010; Boyle et al., 2011).
Timing and duration of the probiotic intervention appears to
be major factor in determining their beneficial effects. Nine of
the 14 RCTs involved both a prenatal and postnatal interven-
tion period, while four studies evaluated only postnatal and one
study examined a prenatal only approach (Boyle et al., 2011).
For the combined prenatal/postnatal probiotic studies, there was
a significant reduction in the cumulative incidence of eczema
and/or IgE-associated eczema in six of the nine published RCTs
(Kalliomaki et al., 2001b; Kukkonen et al., 2007; Wickens et al.,
2008; Niers et al., 2009; Dotterud et al., 2010; Kim et al., 2010) by
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age 2 years. No such effects were reported in the other three studies
(Abrahamsson et al., 2007; Huurre et al., 2008; Kopp et al., 2008).
Interestingly, of these nine prenatal/postnatal studies, a beneficial
effect was found in three of five studies that used LGG with or with-
out other probiotics (LGG (Kalliomaki et al., 2001b); L. rhamnosus
LC705, B. breve Bb99, and Propionibacterium freudenreichii+ the
prebiotic GOS (Kukkonen et al., 2007); LGG, L. acidophilus La-5
and B. lactis Bb12 (Dotterud et al., 2010). In the other two stud-
ies using LGG, one was a study in infants irrespective of a family
history of allergic disease (Huurre et al., 2008) while the other
study by Kopp et al. (2008) found no effect despite utilizing a
similar protocol and LGG dose to that of the landmark study by
Kalliomaki et al. (2001b). A recent meta-analysis of the impact
of maternal probiotic supplementation on eczema development
found a significantly reduced risk in children by 2–7 years of age
with the use of lactobacilli but not with other probiotic species and
strains compared to placebo treatment (Doege et al., 2012). The
remaining four prenatal/postnatal RCTs used a variety of probiotic
species or combinations with varying efficacy. Only the study by
Abrahamsson et al. (2007) showed no difference in eczema, sen-
sitization, or other allergic diseases at 2 years following L. reuteri
treatment. Two studies using different probiotic mixtures reported
a reduction in eczema at 1 year (Kim et al., 2010) and 3 months
(Niers et al., 2009) – however in this latter study, the effect at
3 months did not persist and the outcomes were parental-reported,
not clinician assessed. Wickens et al. (2008) investigated the effects
of two different probiotic interventions in relation to placebo and
reported that L. rhamnosus HN001 but not B. animalis subspecies
lactis HN013 was able to significantly reduce both eczema and
IgE-associated eczema at 2 years. Both of these treatments how-
ever had no impact on sensitization status. This supports the view
that not all probiotics are the same such that they may elicit unique
biological activities. Therefore, selection of probiotic species and
strains should be carefully considered in the design of future clini-
cal trials. It is important to note that despite the beneficial effects of
probiotics in some of the studies, there were also increased risks of
asthma-like symptoms at 2 years in the study by Kopp et al. (2008)
and at 7 years in the study by Kalliomaki et al. (2007), suggesting
that it will be critical to follow these cohorts for several years to
determine any long-term impact (beneficial or otherwise) of the
probiotic effect.
No beneficial effects on eczema or sensitization were found in
three of the four studies using a postnatal treatment approach
(Rautava et al., 2006; Taylor et al., 2007; Soh et al., 2009) with
one study that used L. acidophilus LAVRI-A1 demonstrating an
increased risk of both IgE-associated eczema and atopic sensiti-
zation at 1 year of age (Taylor et al., 2007). The remaining study
found a reduced cumulative incidence of eczema at 13 months
with L. paracasei F19 (West et al., 2009). Overall, these studies
suggest that a postnatal probiotic treatment alone may be insuf-
ficient in reducing the clinical symptoms of allergic disease and
highlights that the importance of the early life period in modu-
lating microbiota and/or immune function begins prior to birth.
In addition, the differences in study designs make it difficult to
draw meaningful conclusions as two studies recruiting high-risk
infants with a family history of allergic disease (Taylor et al., 2007;
Soh et al., 2009) while the other two studies included formula-
fed infants irrespective of allergic disease family history (Rautava
et al., 2006; West et al., 2009). In contrast, the only study to date that
evaluated a prenatal only probiotic approach (using LGG) showed
no evidence for a beneficial effect on eczema or sensitization at
12 months (Boyle et al., 2011). This suggests that a prenatal alone
intervention is insufficient and that inclusion of a postnatal treat-
ment period is required. Alternatively, probiotic species/strains
other than LGG may be effective for the prevention of eczema.
Breastfeeding is one parameter that may be critical in mediating
probiotic effects. Infants who were breastfed by mothers treated
with probiotics during pregnancy and breastfeeding benefited the
most, even when probiotics were not administered directly to them
(Dotterud et al., 2010). Breast milk has important immunoregula-
tory factors such as TGF-β and IgA which can help protect against
the development of allergic disease (Rautava et al., 2006). The
biological mechanisms underpinning these outcomes are not well
understood and require further investigation.
In summary, the use of probiotic bacteria for the prevention
and/or treatment of allergic disease have shown promising results
to date. However, the validity of these findings need to be con-
firmed by further randomized controlled trials. In particular, for
eczema, the timing of the probiotic intervention appears to be
important, with a prenatal component critical for protective effects
(Osborn and Sinn, 2007). Furthermore, a combined prenatal with
early postnatal treatment may be equally effective (Boyle et al.,
2011) while a postnatal alone approach less successful. From the
existing literature, it is clear that several variables can have an
impact on the potential beneficial effects observed, including the
species and strain of probiotic used, geographical differences in
the populations studied as well as the dose and duration of admin-
istration. These differences make drawing conclusions about the
effectiveness of probiotics more difficult. Further studies are there-
fore required to determine the optimal dose, bacterial strain(s),
timing for intervention, and patient populations that would pro-
vide optimal effects in the prevention and/or treatment of allergic
disease.
CONCLUSION
Studies suggest a potential role for selected probiotics in the pre-
vention of eczema, especially IgE-associated eczema. The efficacy
of probiotics for the treatment of allergic disease however requires
further examination. Careful selection of appropriate probiotic
bacteria for future studies will be important, which may be aided
by in vitro, preclinical and pilot studies. In addition, there is insuffi-
cient evidence that probiotics may be of benefit for the prevention
of other allergic conditions. An important limitation of meta-
analyses of studies evaluating probiotics for the prevention of
allergic diseases is that data have been pooled from studies con-
ducted with a variety of different probiotic combinations. Further
clinical studies using the most effective study designs incorpo-
rating prenatal/postnatal treatment and selection of appropriate
probiotic bacteria are required to validate the findings of earlier
studies. Understanding the mechanisms of protection in allergic
disease will greatly assist in developing more targeted strategies for
the prevention or treatment of allergic disease.
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